Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2008

Teixeira Ana L, Ribeiro Ricardo, Cardoso Diana, Pinto Daniela, Lobo Francisco, Fraga Avelino, Pina Francisco, Calais-da-Silva Fernando, Medeiros Rui

Abstract excerpt

PURPOSE: Most prostate cancer patients develop resistance to androgen deprivation treatment, resulting in hormone resistance. Epidermal growth factor (EGF) activates several pro-oncogenic intracellular pathways inducing proliferation, differentiation, and tumorigenesis in epithelial cells. The EGF-EGF receptor pathway seems to be especially relevant in hormone-resistant prostate cancer stage. A single nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Drug Resistance, Neoplasm

Share to Epidermal Growth Factor

Share to Kaplan-Meier Estimate

Share to Polymorphism, Restriction Fragment Length

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 18519765
DOI: 10.1158/1078-0432.CCR-07-5119

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.PMID 18519765Read ↗

Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility.Semantic proximity Read ↗

Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene.Semantic proximity Read ↗

Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease.Semantic proximity Read ↗

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.Semantic proximity Read ↗

Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients.Semantic proximity Read ↗

Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.Semantic proximity Read ↗

Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.Semantic proximity Read ↗

A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.Semantic proximity Read ↗

Association between estrogen and androgen receptor genes and prostate cancer risk.Semantic proximity Read ↗

Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.Semantic proximity Read ↗

Association between EGF promoter polymorphisms and cancer risk: a meta-analysis.Semantic proximity Read ↗

Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.